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son for the loss of data in a register contributes to a bet-
ter knowledge on strategies to discontinue biologics in
stable pts, to a better pharmacovigilance of adverse ef-
fects and to more efficiency in data capture by registries.
Due to data protection reasons it was impossible to have
access to the Pts's death certificates.
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IntroductIon
Patients with inflammatory rheumatic diseases refrac-
tory to conventional synthetic disease-modifying an-
tirheumatic drugs (csDMARDs) have been treated with
biologics for the last two decades, with a dramatic
change in prognosis1. Biologic DMARDs (bDMARDs)
are associated with a higher risk of serious infections
than csDMARDs as well as other adverse effects that war-
rant the need for close monitoring2. A follow-up pro-
gram is an integral aspect of high quality care of these
patients and the failure to maintain regular follow-up is
a major concern. Patients who are lost to follow-up
(LFU) are more likely to experience considerable wors-
ening of the disease, potentially leading to organ dam-
age and increase in health care expenditure3. Thus, it is
crucial that adequate and tight monitoring of efficacy
and safety is organized to assure that patients on bD-
MARDs have an adequate balance between efficacy, risk
of adverse events and costs. Ideally, no patient should be
kept on a drug without clear benefit or if there are un-
acceptable adverse effects. Overlooking these aspects
will translate into unnecessary risks for the patients and
a significant burden to national health services.
When patients become LFU, there is missed infor-
mation in their registries, which is crucial for a com-
prehensive evaluation of the real-world data on the ef-
ficacy and safety of bDMARDs4. Indeed, some patients
stop treatment and thus escape the surveillance of re -
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AbstrAct
Background: The information associated with loss to
follow-up (LFU) patients may affect real-world data
evaluation of the use of biologics that is not being ade-
quately captured in registries.
Methods: We identified all patients (Pts) treated with bi-
ologics in our center who had no visits registered for more
than 6 months, in the Rheumatic Diseases Portuguese
Register, Reuma.pt. We retrieved baseline information
from Reuma.pt and from the hospital electronic clinical
record. We then performed a telephonic interview to
characterize the reasons for LFU at our day care unit. For
Pts unable to be contacted by telephone a letter of invita-
tion to an appointment at the hospital was sent.
Results: From a total of 794 Pts registered in Reuma.pt
at our center with active biologic therapy 227 did not
have any information registered in the last 6 months.
Of this, 36 Pts were on biologic therapy prescribed by
other departments and maintained follow-up in these
departments. 102 Pts had suspended biologic admin-
istration by medical indication and this information
was registered in the hospital electronic clinical records
but not updated in Reuma.pt. For 89 Pts no informa-
tion could be retrieved from either the hospital elec-
tronic clinical record or Reuma.pt and we classified
these Pts as true LFU. 
26 of these LFU Pts were being followed up in an-
other Rheumatology center. 26 of the LFU Pts died. 11
Pts had an adverse effect. 4 Pts of the LFU were con-
sidering to be in remission. We were not able to con-
tact 15 of the LFU pts.
Conclusion: Identifying LFU Pts and clarifying the rea-
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gistries and, on the other hand, some adverse effects
might occur following the LFU and this information
fails to be captured into the registry. In addition, pa-
tients who miss appointments, and ultimately their
regular follow-up, might be more vulnerable to a poor
long-term prognosis3.
Our hypothesis is that identifying the reasons of
LFU will contribute to improve pharmacovigilance and
will eventually lead to an early identification of pa-
tients at risk of LFU and to a better knowledge on
strategies of bDMARD tapering in stable patients. This
will provide relevant information that will improve the
quality of care of these patients.
To our knowledge, there have been no studies in-
vestigating the reasons for LFU in registries of rheumat-
ic patients treated with bDMARDs. In this study, we
aimed to identify the reasons for dropout from follow-
up of patients with inflammatory rheumatic diseases
treated with bDMARDs in our department and to de-
termine these patients’ characteristics.
Methods
A close monitoring program is an integral aspect of high
quality care of rheumatic patients treated with
DMARDs in general, and bDMARDs in particular. At
our department, all patients with inflammatory
rheumatic diseases who are treated with bDMARDs are
followed up in the day-care unit with at least 4 visits per
year. These visits focus on ensuring the efficacy and
safety of these drugs and the prescription is renewed for
another 3 months (subcutaneous bDMARDs) or admi -
nistered on the same day (intravenous bDMARDs) de-
pending on this assessment. Furthermore, patients
keep a regular contact (at least once a year) with their
attending rheumatologist, who ensures an additional
way of monitoring treatment efficacy, safety and ad-
herence, as well as disease activity and damage.
Every appointment at the day-care unit is recorded
with the assistance of the Rheumatic Diseases Por-
tuguese Register (Reuma.pt), a nationwide clinical reg-
ister established and managed by the Portuguese So-
ciety of Rheumatology, in which data from patients
with various rheumatic diseases are recorded5.
Reuma.pt serves as an electronic clinical record with
real-time data, which is then copied into the local hos-
pital electronic file. At the time of initial registration in
Reuma.pt, all patients sign an informed consent, by
which they allow their data to be used for research pur-
poses. Reuma.pt is approved by the local ethics com-
mittee and by the national board for the protection of
personal data. In addition, the ethics committee of our
institution approved the design of this specific study.
As of May 2017, 790 patients were under active bD-
MARDs in our day-care unit. We included all patients
with inflammatory rheumatic diseases with any expo-
sure to bDMARDs prescribed and monitored in our
department, who had the last visit registered in
Reuma.pt more than 6 months before the starting date
of the present study (May 1st, 2017). Information re-
garding diagnosis, age, gender, disease duration and
date of first and last visits to the treating centre was re-
trieved from Reuma.pt. Clinical data collected at the
last appointment was retrieved for the following vari-
ables: erythrocyte sedimentation rate [ESR], c-reactive
protein [CRP]), patient and physician visual analogic
scale (VAS), disease-specific activity scores (disease ac-
tivity score-28 [DAS28], Ankylosing Spondylitis Dis-
ease Activity Score [ASDAS], Systemic Lupus Erythe-
matosus Disease Activity Index [SLEDAI], Birmingham
Vasculitis Activity Score [BVAS]) and functional scores
(Health Assessment Questionnaire [HAQ]). Finally, we
identified data on current and previous bDMARDs ex-
posure and their safety, as assessed through adverse
events and reasons for bDMARDs discontinuation reg-
istered in Reuma.pt. The local (hospital) and national
(Health Data Platform) electronic clinical record was
also revised to identify possible reasons for LFU that
might have escaped Reuma.pt registration.
For patients without information in any of the elec-
tronic registers, a telephonic interview was performed
to characterize the reasons associated with LFU. An
appointment at our department was offered and fur-
ther evaluation was pursued for patients who wanted
to return to our care. For patients not reachable by
telephone, a letter of invitation to a clinic appointment
at our department was proposed.
Descriptive statistics were applied to characterize
this cohort. Normally distributed variables are pre-
sented as mean and standard deviation and non-nor-
mal variables are presented as median and interquar-
tile range. All the analyses were performed using Stata
14.2 for Mac.
results
From a total of 790 patients registered in Reuma.pt at
our centre with active biologic therapy, 227 (28.7%)
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The reasons for LFU are represented in Figure 2. The
most frequent causes of LFU were follow-up at ano ther
Rheumatology centre (n=26; 29.2%) and death (n=26;
29.2%). In 15 cases (16.9%) patients could not be con-
tacted by telephone nor attended the appointment offe -
red; therefore, no additional data could be retrieved.
Twenty-six (29.2%) of these LFU patients were being
followed in other Rheumatology centres (Table I). The
reasons for this change are represented in Figure 3. 15
patients (16.9%) had transferred their follow-up at a
newly opened and closer Rheumatology Department;
6 (6.7%) had moved to another city and 5 patients
(5.6%) had administrative problems related to our De-
partment/Hospital.
Twenty-six (29.2%) patients died, at a mean age of
66.2 (± 14.7) years (Table I). The mean disease dura-
tion was 14.3 (± 10.5) years and the most common di-
agnosis was RA (n=21; 81.8%). The mean duration of
bDMARDs therapy was 5.9 (± 3.5) years: 69.2% were
on anti-TNF therapy, 15.4% on anti-CD20 therapy and
11.5% on anti-interleukin-6R therapy at the time of
the last clinic appointment (Table I). The cause of death
was identified in only 4 patients, through telephone in-
terview with their relatives: myocardial infarction
(n=1), lung cancer (n=1), peritonitis following hepa tic
did not have any information registered in the previous
6 months (Figure 1). Of those, 36 patients (15.9%)
were still on bDMARDs prescribed by other depart-
ments (dermatology and gastroenterology) in our hos-
pital and maintained follow-up in these departments.
One-hundred and two patients (44.9%) had suspend-
ed bDMARDs according to medical recommendation,
and this information was registered in the hospital elec-
tronic clinical record but not updated in Reuma.pt.
These patients maintained follow-up in our department
and thus were not classified as true LFU. We have up-
dated this information at Reuma.pt. Eighty-nine pa-
tients (39.2% of the 227 patients and 11.3% of the to-
tal of 790 patients) had no information in the hospital
electronic clinical record or Reuma.pt and these pa-
tients were classified as true LFU patients. Here we pre-
sent the description of these 89 patients LFU from our
centre.
The demographic and clinic characteristics of these
LFU patients are summarized in Table I. Twenty-nine
of the total 89 LFU (32.6%) were male with a mean age
of 51.3 (± 20.0) years. Mean disease duration was 15.7
± 10.3 years and the mean duration of biologic thera-
py was 5.5 ± 3.5 years. The last biologic used was in the
majority of the cases etanercept (24.7%) (Table I).
790 patients registered 
in Reuma.pt 
No information in the hospital electronic







No information registered in
Reuma.pt in last 6 months
36 patients (4.5%) were still on 
bDMARDs prescribed by
other department
102 patients (12.9%) suspended
bDMARD acording to medical
recommendation (information in the
hospital electronic clinical record)
FIGure 1. Process to reach the number of true loss to follow up
Reuma.pt: Rheumatic Diseases Portuguese Register; bDMARDs: biologic disease-modifying antirheumatic drugs
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cyst rupture (n=1) and acute pulmonary oedema after
lower limb amputation surgery (n=1). None of these 4
patients were on bDMARD therapy at the moment of
death. None of the patients were on active biologic
treatment at the time of the death. However, we were
not able to precisely determine how much time had
passed since the last recorded appointment and the
time of death; likewise, we could not retrieve the re-
maining 22 patients’ causes of death, as we were not au-
thorized to assess the death certificate.
Eleven patients (12.4%) had stopped biologic thera -
py and abandoned follow-up by their own decision 
after experiencing adverse effects attributed by the pa-
tient to the use of bDMARDs, although they were not
reviewed by their assistant rheumatologist afterwards
(Table I, Figure 4). Six patients (6.7%) had infectious
complications, either of the skin (n=3, 3.4%) or the
urinary tract (n=3, 3.4%). Of those, 2 patients had to
be admitted to the hospital: one PsA patient treated
with adalimumab who had an urosepsis and one RA
patient treated with tocilizumab who acquired a
pyelonephritis. Two out of the 3 patients classified as






















































FIGure 3. Reasons for follow up in others centres 
A: follow-up at a newly open and closer Rheumatology 
Department; B: moved to another city; C: administrative problems

























FIGure 4. Reasons for follow up in others centres  
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wound: one of them was an RA patient treated with
etanercept who was submitted to an orthopaedic pro-
cedure of the foot and the other was a SpA patient trea -
ted with golimumab who had a laparoscopic cholecys-
tectomy. The third patient had an infection of lower
limbs’ ulcers.
The remaining patients stopped the drug because of
skin reactions (n=5, 5.6%). Those reactions were not
observed by a physician or registered in Reuma.pt or
electronic clinical record.
Four patients (4.5%) assumed that they were in re-
mission and decided to stop the drug and medical fol-
low-up by their own initiative. When contacted, all of
them believed that the disease was inactive without the
need for biological treatment.
Regarding the 7 other patients with miscellaneous
reasons for LFU (Table I): 2 patients (2.3%) had socio
economic issues and for these reasons were being fol-
lowed-up only by their general practitioner, having
stopped bDMARD therapy and were feeling that their
disease was adequately controlled; one was currently in
jail and decided not to continue medical therapy or
medical follow-up because he was not feeling the need
for active treatment; two patients preferred to replace
the biologic with non-conventional therapies, believing
that they would be sufficient to control their underly-
ing disease and stated that their symptoms were ade-
quately controlled; two patients quit medical follow-up
because they missed their last appointment but they
were experiencing worsening of their clinical condi-
tion and were interested in resuming follow-up at our
centre.
As there were missing data regarding disease activi-
ty at the last appointment in Reuma.pt, we decided to
describe the data referring only to RA and SpA patients
(Table II). Furthermore, the number of patients was in-
adequate for a statistical analysis of these data.
Regarding patients who considered themselves to be
in remission, we found that in the last clinical record,
one of them had high disease activity (SpA patient with
ASDAS 3.0), other had moderate disease activity (RA
patient with DAS28-ESR 4.257) and two patients were
in remission (a SpA patient with ASDAS <1.3 and a Still
disease patient with no active joints or extra-articular
symptoms and negative inflammatory markers).
dIscussIon
To the best of our knowledge, this is the first study ex-
ploring the reasons for LFU in patients under biologic
therapy.
LFU patients may represent a relevant bias that in-
terferes with appropriate pharmacovigilance and as-
sessment of efficacy outcomes in patients under bD-
MARDs4.
tAble II. dIseAse ActIvIty At the lAst vIsIt oF lFu pAtIents wIth rA And spA 
Patients followed in Patients with 
other centres Patients who died adverse effects
Disease activity, median (IQR) RA (N=11) SpA (N=5) RA (N=21) SpA (N=2) RA (N=5) SpA (N=4)
PhVAS 20 30 37 45 20 (20-25) 15 
(10-30) (20-40) (27-44) (32.5-57.5) (7.5-22.5)
PtVAS 40 30 50 47.50 50 50 
(30-50) (20-40) (30-70) (33.8-61.3) (45-52.5) (45-60)
DAS28-ESR 3.17 – 3.39 – 2.44 –
(1.94-3.33) (2.73-3.91) (2.05-2.59)
ASDAS-CRP – 2.55 – 2.29 – 1.69 
(2.37-2.73) (1.8-2.8) (1.2-2.25)
ERS (mm/h) 32 8.49 31.49 16 29 8 
(15-51) (8.25-8.75) (14-40.8) (13-19) (16-38.8) (8.0-12.75)
CRP (mg/dl) 1.38 6.39 0.51 0.84 0.35 0.21 
(0.04-1.95) (5.1-7.7) (0.16-2.04) (0.65-1.02) (0.19-0.56) (0.19-0,38)
ASDAS CRP: Ankylosing Spondylitis Disease Activity Score, C-reactive protein; CRP: C-reactive protein; DAS28 ESR: Disease activity 
score-28, erythrocyte sedimentation rate; ESR: Erythrocyte sedimentation rate; IQ: Interquartile; PhGA: Physician global assessment; 
PtGA: Patient global assessment; RA: Rheumatoid arthritis; SpA: Spondyloarthritis.   
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Reuma.pt had missing data, namely patients who
had already suspended bDMARDs for various reasons
known to the attending physician (infectious cause,
other adverse effects, change of residency, emigration,
amongst others). However, this information had not
been registered and although these were not true LFU
to our care, this represented missing information, cru-
cial to comprehensive pharmacovigilance.
Concerning the true LFU patients at our centre, most
had a diagnosis of RA, mean age 51.3 (±20.0) years and
there was a predominance of female gender. A study
that evaluated the frequency of LFU from medical care
of patients with rheumatic diseases also showed that
LFU was higher in female gender3. The most common
reason for LFU was moving to another Rheumatology
centre in order to have continuous medical care at a
newer and closer Rheumatology Department. 
We identified 4 LFU patients who stopped treatment
because they believed they were on remission and de-
cided to abandon medical care and pharmacological
therapy. However, when assessing disease activity at
the last appointment, it was found that one patient had
high disease activity, other moderate, and only two
were in true remission.
When asked about returning to their consultations,
most patients were willing to resume follow up, name-
ly patients who had an adverse effect and patients who
loss appointments and loss follow-up.
Of the 26 patients who died, we only identified the
cause of death of 4. This is an important concern re-
garding pharmacological safety. This missing informa-
tion is crucial for a comprehensive real-world data eval-
uation of the use of bDMARDs. Unfortunately, it was
not possible to have access to the patient’s death cer-
tificates, which is a major limitation of this analysis.
Other relevant limitations were the lack of information
on the education level and socio-economical back-
ground, missing data, sample size and the impossibili -
ty of having precise information available on the time
interval between the last treatment administered and
death.
conclusIon
The information hidden in these LFU patient’s registries
is crucial for a comprehensive real-world data evalua-
tion of the use of biologics, regarding efficacy, safety
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